Thrombolytic therapy clinical applications

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 283-311

  Baker Jr , William F ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KERN MEDICAL CENTER   (United States)

^c California Clinical Thrombosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; DESULFATOHIRUDIN; DIPYRIDAMOLE; EFEGATRAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LANOTEPLASE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROUROKINASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ANAPHYLAXIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; FEVER; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HYPOTENSION; LUNG EMBOLISM; META ANALYSIS; MULTICENTER STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

AMINO ACID SEQUENCE; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037319316     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00084-9     Document Type: Review

References (175)

1. Fletcher A, Sherry S, Alkjaersig N, et al. The maintenance of a sustained thrombolytic state in man: II. Clinical observations in patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959;38:11-9.
2. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
3. Bick R. Physiology of hemostasis. In: Bick R, editor. Disorders of hemostasis and thrombosis: clinical and laboratory practice. Chicago: ASCP Press; 1992. p. 1-27.
4. McNicol G. The fibrinolytic system. Postgrad Med J 1973;49S:10S-7S.
5. Aoki N, Moroi M, Matsuda M. The behavior of alpha-2-plasmin inhibitor in fibrinolytic states. J Clin Invest 1977;60:361-8.
6. Bick R, Physiology of hemostasis and thrombosis. In: Disorders of hemostasis and thrombosis: principles of clinical practice. New York: Thieme, Inc.; 1985. p. 1-30.
7. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI 14) trial. Circulation 1999;99:2720-32.
8. Figueredo V, Amidon T, Wolfe C. Thrombolysis after acute myocardial infarction: who should be added to inclusion criteria? Postgrad Med 1994;96:30-40.
9. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-22.
10. Van de Werf CC, Luyten A, Houbracken K, et al. Safety assessment of a single bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999;137:786-91.
11. Johnson A, McCarty W. The lysis of artificially induced intravascular clots in man by intravenous infusion of streptokinase. J Clin Invest 1959;38:1627-43.
12. Collen D. Report of the Subcommittee on Fibrinolysis; San Diego, CA, July 13, 1985. Thromb Haemost 1985;54:893.
13. Eisenberg P, Miletich J, Sobel B, et al. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis 1991;5:217-24.
14. Hoffmeister HM, Szabo S, Kastner C, et al. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on kallikrein system and plasmin. Circulation 1998;98:2527-33.
15. Rapold H. Promotion of thrombin activity by thrombolytic therapy without simultaneous anti-coagulation. Lancet 1990;1:481-2.
16. Davies M, Thomas A, Knapman P. Intra-myocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-27.
17. Moliterno DJ, Harrington RA, Krucoff MW, et al. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM trial [abstract]. Circulation 1996;94(Suppl 1):553.
18. Nicolini FA, Lee P, Rios G, et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89: 1802-9.
19. Ohman EM, Kleiman N, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose-ranging trial. Circulation 1997;95: 846-54.
20. Roux S, Tschoff T, Kuhn H, et al. Effects of heparin, aspirin, and synthetic glycoprotein IIb/IIIa receptor antagonist on coronary reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. Journal of Pharmacology and Experimental Therapeutics 1993;264:501-8.
21. Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thrombotic Diathesis and Haemorrhage 1968;19:474-82.
22. Fitzgerald D, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-50.
23. Terres W, Unmus S, Mathey DG, et al. Effect of streptokinase, urokinase and tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. Cardiovasc Res 1990;67:1175-81.
24. Coulter S, Cannon C, Ault K, et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from Thrombolysis in Myocardial Infarction (TIMI) 14. Circulation 2000;101: 2690-5.
25. Kleiman N, Ohman M, Califf R, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: results of the TAMI 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
26. White HD. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. Am J Cardiol 1998;82:57P-62P.
27. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 1997;31:1466-73.
28. Nordt TK, Moser M, Kohler B, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haemost 1998;80: 881-6.
29. DeWood M, Spores J, Notshe R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
30. Agnelli G. Thrombolytic and antithrombotic therapy in myocardial infarction: main achievements and future perspectives. Int J Cardiol 1995;49S:77S-87S.
31. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545-9.
32. Chesebro JH, Knaterud G, Roberts R, et al. Thrombolysis in acute myocardial infarction (TIMI) trial, phase 1: a comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-54.
33. Second International Study of Infarct Survival. (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-60.
34. PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-8.
35. Granger C, Califf R, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992;44:293-325.
36. Sheehan FH, Brawnwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial. Circulation 1987;75:817-29.
37. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
38. The GUSTO V Investigators. A comparison of heparin plus full, bolus dose reteplase with half-dose reteplase plus abciximab plus heparin in patients with acute myocardial infarction. Lancet 2001;357:1905-14.
39. Verstraete M, Bleifeld W, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985;1:842-7.
40. Furlan A, Higashida F, Wechsler L, et al. A randomized trial of intra-arterial prourokinase for acute ischemic stroke due to middle cerebral artery occlusion. JAMA 1999;282:2003-11.
41. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000;283:2686-92.
42. Chaise L, Camerota A, Soulen R, et al. Selective intra-arterial streptokinase therapy in the immediate postoperative period. JAMA 1982;247:2397.
43. Six A, Louwerenburg H, Braams R, et al. A double-blind randomized multicenter dose-ranging trial of streptokinase in acute myocardial infarction. Am J Cardiol 1990;65:119-23.
44. Granger CB, White HD, Bates ER, et al. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994;74:1220-8.
45. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)-1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i: 397-401.
46. The ISAM Trial Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314: 1465-71.
47. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
48. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. (GISSI-2), and International Study Group. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J 1992;123:1692.
49. Fibrinolytic Trialist's Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
50. The TIMI Study Group. Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings. N Engl J Med 1985;312:932-6.
51. Neuhaus R, VonEssen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19:885-91.
52. Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
53. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
54. Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombolysis in acute myocardial infarction. Chest 2001;119:253S-77S.
55. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1604-10.
56. The Continuous Infusion versus Double-bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997;337:1124-30.
57. Mark DB, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared to streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
58. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment of acute myocardial infarction. Ann Intern Med 1998;129: 597-604.
59. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891.
60. Smalling R, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.
61. The Global Use of Strategies to Open Occluded Coronary Arteries. (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337:1118-23.
62. Cannon C, McCabe C, Gibson C, et al. TNK-tissue plasminogen activator in acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-6.
63. Barron HV, Fox N, Berioli S, et al. Comparison of intracranial hemorrhage rates in patients treated with rt-PA and TNKt-PA: impact of gender, age and low body weight. Circulation 1999; 100:1-11.
64. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus reteplase. Circulation 1998;98:2117-25.
65. The InTIME-II Investigators. Intravenous NPA for the treatment of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-13.
66. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin in Myocardial Infarction (TIMI) 9b trial. Circulation 1996;94:911-21.
67. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
68. Markwardt F. Hirudin and its derivatives as anticoagulant agents. Thromb Haemost 1991;66: 141-52.
69. White H, Aylward P, Frey M, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997;96: 2155-61.
70. Jang IK, Giugliano RP, Massey T, et al. A randomized, blinded study of two doses of Novastin (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue-plasminogen activator (accelerated administration) in acute myocardial infarction: rationale and design of the Myocardial Infarction using Novastin and T-PA (MINT) study. Journal of Thrombosis and Thrombolysis 1998;5:49-52.
71. Fung A, Lorch G, Cambier P, et al. Efegetran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. Am Heart J 1999;138:696-704.
72. Thrombin Inhibition in Myocardial Ischemia (TRIM) Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a randomized, dose-finding study. Eur Heart J 1997;18:1416-25.
73. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIa/IIIb inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and reperfusion Gain in Myocardial infarction (PARADIGM). J Am Coll Cardiol 1998;32: 2003-10.
74. Topol EJ. Toward a new frontier in myocardial perfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-8.
75. Strategies for Patency Enhancement in the Emergency Department (SPEED) Trial Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: Strategies for Patency Enhancement in the Emergency Department (SPEED). Circulation 2000;101:2788-94.
76. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-13.
77. McLean J. The thromboplastic action of cephalin. Am J Physiol 1912;41:250-7.
78. Weitz J, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
79. Bleich S, Nichols T, Schumacher R, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-7.
80. Hsia J, Hamilton W, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.
81. Ryan T, Antman EM, Brooks N, et al. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
82. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular mural thrombus formation and arterial embolism after acute myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997;39:962-9.
83. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with the use of low-molecular - weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77:1145-8.
84. Ross AM, Molhoek P, Lundergan C, et al. A randomized comparison of low-molecular-weight heparin enoxaparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART II). Circulation 2001;104:648-52.
85. Vu T, Hung D, Wheaton V, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
86. Rydel T, Ravichandran K, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human-thrombin. Science 1990;249:277-80.
87. Leopold J, Keaney J, Loscalzo J. Pharmacology of thrombolytic agents. In: Loscalzo J, Schafer AI, editors. Thrombosis and hemorrhage. Baltimore: Williams and Wilkins; 1998. p. 1215-58.
88. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
89. Neuhaus K, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeirsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-42.
90. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34:966-73.
91. Theroux P, Perez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91:2132-9.
92. White H, Van De Werf F. Thrombolysis for acute myocardial infarction. Circulation 1998;97: 1632-46.
93. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombinspecific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-63.
94. del Zoppo G, Poeck P, Pessin M. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
95. Fieschi C, Argentino C, Weschler L, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311-22.
96. Siesjo B. Pathophysiology and treatment of focal cerebral ischemia. I: pathophysiology. J Neurosurg 1992;77:169-84.
97. Brott T, Broderick J, Kothari R. Thrombolytic therapy for stroke. Curr Opin Neurol 1994;7: 25-35.
98. Levine S, Brott T. Thrombolytic therapy in cerebrovascular disorders. Prog Cardiovasc Dis 1992;34:235-62.
99. Wardlaw JM, Warlow C. Thrombolysis in acute ischemic stroke: does it work? Stroke 1992;23:1826-39.
100. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
101. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Stroke Study (ECASS). JAMA 1995;274:1017-25.
102. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II): second European-Australian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
103. Clark W, Albers G, Madden K, et al. The rt-PA (alteplase) 0 to 6-hour acute stroke trial, Part A: results of a double-blind, placebo-controlled multicenter study. Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 2000;31:811-6.
104. Clark W, Wissman S, Albers G, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3-5 hours after symptom onset. JAMA 1999;282:2019-26.
105. Multicenter Acute Stroke Trial - Italy. (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346:1509-14.
106. The Multicenter Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
107. del Zoppo G, Higashida R, Furlan R, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
108. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999;53(Suppl 4):S3-14.
109. Wardlaw J, Warlow C, Counsell C. Systematic review of evidence of thrombolytic therapy for acute ischemic stroke. Lancet 1997;350:607.
110. Albers G, Amarenco P, Easton D, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119S:300S-20S.
111. Goldhaber SZ, Kessler C, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-8.
112. Marder V. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979;90:802-8.
113. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective trial. Act Med Scand 1982;211:65-8.
114. Common H, Seaman A, Rosch J, et al. Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study. Angiology 1976;27:645-54.
115. Elliott M, Immelman E, Jeffrey P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979;66:383-843.
116. Immelman E, Jeffrey P. The post-phlebitic syndrome. Pathophysiology prevention and management. Clin Chest Med 1984;5:537-50.
117. Johanson L, Nylander G, Hedner U, et al. Comparison of streptokinase with heparin: late results in the treatment of deep vein thrombosis. Acta Medica Scandinavica 1979;296:93-8.
118. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
119. Watz R, Savidge G. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. Acta Med Scand 1979;205:293-8.
120. Marder V, Sherry S. Thrombolytic therapy: current status. N Engl Med 1988;318:1512-20; 1585-94.
121. Bell WR, Black EB, DeMets D. Urokinase Pulmonary Embolism Trial: Phase I results. JAMA 1970;214:2163-72.
122. Bell WR, Black EB, DeMets D. Urokinase Pulmonary Embolism Trial: Phase II results. JAMA 1974;229:1606-13.
123. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose alteplase versus conventional alteplase for pulmonary thrombolysis: an international multicenter randomized trial. Bolus Alteplase Pulmonary Embolism Group. Chest 1994;106:718-24.
124. Goldhaber SZ, Haire W, Feldstein M. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-11.
125. Goldhaber SZ, Meyerovitz M, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990;88:235-40.
126. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998;31:1057-63.
127. Kostantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major embolism. Am J Cardiol 1998;82:966-70.
128. Sharma G, Burleson V, Sasahara A, et al. Effect of thrombolytic therapy on pulmonary blood capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303:842-5.
129. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999;138:39-44.
130. Hyers T, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119S:176S-93S.
131. Goldhaber SZ. Management of deep vein thrombosis and pulmonary embolism. Clinical Cornerstones 2000;2:47-55.
132. Verstraete M, Miller G, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77:353.
133. Dalen JE, Alpert JS. Thrombolytic therapy for pulmonary embolism: is it effective? is it safe? when is it indicated? Arch Intern Med 1997;157:2550-6.
134. McConnell M, Solomon S, Rayan M, et al. Regional fight ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996;78:469-73.
135. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation 1996;93:2212-45.
136. Nasraway S, Kabani N, Lawrence K. Thrombolytic therapy for pulmonary embolism: reversal of shock in the early postoperative period. Pharmacotherapy 1994;14:616.
137. Severi P, LoPinto G, Poggio R, et al. Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients. Surg Neurol 1994;42:469.
138. Mazeka P, Oakley C. Massive pulmonary embolism in pregnancy treated with streptokinase and percutaneous catheter fragmentation. Eur Heart J 1994;15:1281.
139. Bottinger B, Reim S, Diezel G, et al. High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism. Chest 1994;106:1281.
140. Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest. Arch Intern Med 2000;160:1529-35.
141. Schmitz-Rode T, Janssens U, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000;36:375-80.
142. Turpie AG, Levine M, Hirsh J, et al. Tissue plasminogen activator vs heparin in DVT. Results of a randomized trial. Chest 1990;97:172S-5S.
143. Bjamason H, Kruse J, Azinger D, et al. Iliofemoral deep vein thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol 1997; 8:405.
144. Camerota A, Aldridge S, Cohen G, et al. A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis. J Vasc Surg 1994;20:244.
145. Semba C, Dake M. Iliofemoral deep venous thrombosis: aggressive therapy with catheterdirected thrombolysis. Radiology 1994;191:487.
146. Vehaeghe R, Stockx L, Lacroix H, et al. Catheter-directed lysis of iliofemoral vein thrombosis with the use of rt-PA. Eur Radiol 1997;7:996.
147. Mewissen M, Seabrook G, Meissner M, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999;211:39.
148. Amery A, Deloof W, Vermylen J, et al. Outcome of recent thromboembolic occlusion of limb arteries treated with streptokinase. Br J Med 1970;4:639.
149. Berni G, Bandyk D, Zierler R, et al. Streptokinase treatment of acute arterial occlusion. Ann Surg 1983;198:185.
150. Cotton L, Flute P, Tsapogas M. Popliteal artery thrombosis treated with streptokinase. Lancet 1962;2:1081.
151. Hallet J, Greenwood L, Yrizzary J, et al. Statistical determinants of success and complications of thrombolytic therapy for arterial occlusion of lower extremity. Surgical Gynecology and Obstetrics 1985;161:431.
152. Hess H, Ingrisch H, Mietaschk A, et al. Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 1982;307:1627.
153. Sicard G, Schier J, Totty W, et al. Thrombolytic therapy for acute arterial occlusion. J Vasc Surg 1985;2:65.
154. Verstraete M, Vermylen J, Donati M. The effect of streptokinase infusion of chronic arterial occlusions and stenosis. Ann Intern Med 1971;74:377.
155. Ouriel K, Shortell C, de Weese J, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19:1021.
156. Ouriel K, Veith F, Sasahara A, et al. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338:1105.
157. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial. Ann Surg 1994;220:251.
158. Gardiner GJ, Koltun W, Kandarpa K, et al. Thrombolysis of occluded femoropopliteal grafts. Am J Roentgenol 1986;147:621.
159. van Breda A, Robison J, Feldman L, et al. Local thrombolysis in the treatment of arterial graft occlusions. J Vasc Surg 1984;1:103-8.
160. Belkin M, Belkin B, Bucknam C, et al. Intra-arterial fibrinolytic therapy-efficacy of streptokinase vs. urokinase. Arch Surg 1986;121:769.
161. McNamara T, Fischer J. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR Am J Roentgenol 1985;144:769.
162. Heymans S, Venderschueren S, Verhaege R, et al. Outcome and one year follow-up of intraarterial staphylokinase in 191 patients with peripheral arterial occlusions. Thromb Haemost 2000;83:666.
163. Marder VJ. Thrombolytic therapy: foundations and results. In: Colman R, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basic principles and clinical practice. 4th edition. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1475-95.
164. Kroger K, Buss D, Rudofsky G. Retrospective analysis of rt-PA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology 2000;52:377-83.
165. Murr K, Rhoney D, Coplin W. Urokinase in the treatment of intraventricular hemorrhage. Ann Pharmacother 1998;32:256-8.
166. Lee W, Hill B, Harris EJ, et al. Surgical intervention is not required for all patients with subclavian vein thrombosis. J Vasc Surg 2000;32:57-67.
167. Urschel Jr HC, Razzuk MA. Paget-Schroetter syndrome: what is the best management? Ann Thorac Surg 2000;69:1663-8.
168. Bhattacharjya T, Olliff S, Bhattacharlya S, et al. Percutaneous portal vein thrombolysis and endovascular stent for management of post transplant portal venous conduit thrombosis. Transplantation 2000;69:2195-8.
169. Leebeek F, Lameris J, van Buren H, et al. Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis. Br J Haematol 1998;102:929-31.
170. Shapira Y, Herz I, Vaturi M, et al. Thrombolysis is an effective and safe therapy in stuck mitral valves in the absence of high-risk thrombi. J Am Coll Cardiol 2000;35:1874-80.
171. Silber H, Khan S, Matloff J, et al. The St. Jude valve. Thrombolysis as the first line of therapy for cardiac valve thrombosis. Circulation 1993;87:30-7.
172. Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10B trial. Circulation 1998;98:2805-14.
173. Carnendran L, Steinberg J. Does an open infarct-related artery after myocardial infarction improve electrical stability? Prog Cardiovasc Dis 2000;42:439-54.
174. Investigators of the International Joint Efficacy Comparison of Thrombolytics (INJECT). Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346:329-36.
175. Lee L. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7-13.